196 related articles for article (PubMed ID: 21349401)
21. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of uncontrolled hypertension in patients with Fabry disease.
Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
Am J Hypertens; 2006 Aug; 19(8):782-7. PubMed ID: 16876675
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular complications of obesity surgery in patients with increased preoperative cardiac risk.
Afolabi BA; Novaro GM; Szomstein S; Rosenthal RJ; Asher CR
Surg Obes Relat Dis; 2009; 5(6):653-6. PubMed ID: 19747884
[TBL] [Abstract][Full Text] [Related]
25. Cardiac manifestations of Anderson-Fabry disease in children and adolescents.
Kampmann C; Wiethoff CM; Whybra C; Baehner FA; Mengel E; Beck M
Acta Paediatr; 2008 Apr; 97(4):463-9. PubMed ID: 18363956
[TBL] [Abstract][Full Text] [Related]
26. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
[TBL] [Abstract][Full Text] [Related]
27. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
[TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
[TBL] [Abstract][Full Text] [Related]
29. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
[TBL] [Abstract][Full Text] [Related]
30. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
31. Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement therapy on kidney function.
Ries M; Schiffmann R
Arch Dermatol; 2005 Jul; 141(7):904-5; author reply 905-6. PubMed ID: 16027312
[No Abstract] [Full Text] [Related]
32. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
33. Progression of Fabry cardiomyopathy despite enzyme replacement therapy.
Pieroni M; Camporeale A; Della Bona R; Sabini A; Cosmi D; Magnolfi A; Bolognese L
Circulation; 2013 Oct; 128(15):1687-8. PubMed ID: 24100483
[No Abstract] [Full Text] [Related]
34. Diagnosis and treatment of the cardiovascular consequences of Fabry disease.
Baig S; Vijapurapu R; Alharbi F; Nordin S; Kozor R; Moon J; Bembi B; Geberhiwot T; Steeds RP
QJM; 2019 Jan; 112(1):3-9. PubMed ID: 29878206
[TBL] [Abstract][Full Text] [Related]
35. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.
Kaneski CR; Moore DF; Ries M; Zirzow GC; Schiffmann R
Neurology; 2006 Dec; 67(11):2045-7. PubMed ID: 17159117
[TBL] [Abstract][Full Text] [Related]
36. Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease.
El Sayed M; Hirsch A; Boekholdt M; van Dussen L; Datema M; Hollak C; Langeveld M
Heart; 2021 Dec; 107(23):1889-1897. PubMed ID: 33568430
[TBL] [Abstract][Full Text] [Related]
37. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.
Eng CM; Fletcher J; Wilcox WR; Waldek S; Scott CR; Sillence DO; Breunig F; Charrow J; Germain DP; Nicholls K; Banikazemi M
J Inherit Metab Dis; 2007 Apr; 30(2):184-92. PubMed ID: 17347915
[TBL] [Abstract][Full Text] [Related]
38. Fabry Disease: An Uncommon Cause of Renal Failure.
López PD; Andreias L; Astiazarán-Symonds E; Chalabi J
Am J Med; 2017 Sep; 130(9):e389-e390. PubMed ID: 28389313
[No Abstract] [Full Text] [Related]
39. Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis.
Shi Q; Chen J; Pongmoragot J; Lanthier S; Saposnik G
J Stroke Cerebrovasc Dis; 2014; 23(5):985-92. PubMed ID: 24126289
[TBL] [Abstract][Full Text] [Related]
40. The impact of a prior history of cardiovascular events on outcomes in patients on renal replacement therapy.
Bayliss G; Roshan B; Ventrapragada S; Weinrauch LA; Gleason RE; D' Elia JA
Int J Cardiol; 2012 May; 157(1):146-8. PubMed ID: 22464248
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
